Tirzepatide, a newer dual GLP-1/GIP receptor agonist, demonstrated even larger reductions in some studies, with systolic decreases reaching 68 mmHg in overweight patients
Bottom: The location of the backbone amide hydrogen bond on Asn28 is shown in green in the zoomed in image
Clinical Highlights Phase 2 data showed that individuals receiving the 4.8 mg dose weekly for 46 weeks achieved nearly 19 % average weight loss vs placebo
[2] [5] However, some patients report variations in appetite suppression during the weekly dosing cycle, with effects potentially being strongest in the first few days post-injection and diminishing slightly towards the end of the week
Both substances are recognised as inducers of autophagy (Reference Hofer, Daskalaki and Bergmann6, Reference Kriebs31)
Some may cause side effects like increased heart rate, jitteriness, or digestive issues